[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369500-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369500-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","frequency-of-microsatellite-instability-in-gynecologic-cancers-and-the-efficacy-of-immune-checkpoint-inhibitors-treated-real-world-data-from-a-single-gynecologic-center","Frequency of microsatellite instability in gynecologic cancers and the efficacy of immune checkpoint inhibitors treated - real-world data from a single gynecologic center","","Retrospective analysis from a single gynecologic center evaluated the incidence of microsatellite instability-high (MSI-H) among patients with gynecologic cancers and assessed outcomes of immune checkpoint inhibitors (ICIs) for MSI-H in advanced or recurrent disease. Among 1333 patients, MSI-H frequencies varied by cancer type, including cervical, endometrial, and ovarian/tubal–peritoneal cancers, and were further characterized by histologic and molecular classifications. In the subgroup receiving ICIs, objective response rate, time to response, progression-free survival, and overall survival were reported, with additional endometrial cancer comparisons by MSI status. The study concluded that MSI-H distribution was defined across major gynecologic tumors and that ICIs provided clinical benefit, with endometrial effects potentially consistent regardless of MSI status.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/frequency-of-microsatellite-instability-in-gynecologic-cancers-and-the-efficacy-of-immune-checkpoint-inhibitors-treated-real-world-data-from-a-single-gynecologic-center/369500/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/frequency-of-microsatellite-instability-in-gynecologic-cancers-and-the-efficacy-of-immune-checkpoint-inhibitors-treated-real-world-data-from-a-single-gynecologic-center/369500.png","ImageObject",300,407,{"name":42,"@type":43},"Alex Sinclair","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of this study?","Question",{"text":63,"@type":64},"The study evaluated the incidence of MSI-H in patients with gynecologic cancers at a single center and investigated the effect of immune checkpoint inhibitors (ICIs) in treating MSI-H in advanced or recurrent disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was MSI-H frequency distributed among the major gynecologic cancer types?",{"text":68,"@type":64},"Among 1333 analyzed patients, MSI-H frequency was reported for cervical cancer (1.3%), endometrial cancer (25.7%), and ovarian/tubal and peritoneal cancer (10.5%). It also varied by histologic type.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical benefit did ICIs show for MSI-H patients?",{"text":72,"@type":64},"For patients treated with ICIs, the objective response rate (ORR) was reported along with time to response and survival outcomes including progression-free survival (PFS) and overall survival (OS). The study concluded that ICIs provided clinical benefit in advanced or recurrent gynecologic cancer patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369500,1790536065,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Original Research PUBLISHED 09 May 2025  \nDOI 10.3389/fimmu.2025.1567824  \nOPEN ACCESS  \nEDITED BY  \nKanjoormana Aryan Manu,  \nAmala Cancer Research Centre, India  \nREVIEWED BY  \nSong Yizuo,  \nFirst Afﬁliated Hospital of Wenzhou Medical University, China  \nLiubov A. Tashireva,  \nTomsk Cancer Research Institute (RAS), Russia  \n*CORRESPONDENCE  \nCheng Wang  \n [hxeycc@126.com](hxeycc@126.com)  \nRECEIVED 28 January 2025  \nACCEPTED 15 April 2025  \nPUBLISHED 09 May 2025  \nCITATION  \nKuang W, Zeng J, Tong L, Liu Q, Sun H, Feng M, Liang D, Wang W and Wang C (2025) Frequency of microsatellite instability in gynecologic cancers and the efﬁcacy of immune checkpoint inhibitors treated: realworld data from a single gynecologic center. Front. Immunol. 16:1567824 .  \ndoi: 10.3389/fimmu.2025.1567824  \nCOPYRIGHT  \n© 2025 Kuang, Zeng, Tong, Liu, Sun, Feng, Liang, Wang and Wang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nFrequency of microsatellite instability in gynecologic cancersand the efﬁcacy of immune checkpoint inhibitors treated:  \nreal-world data from a single gynecologic center  \nWei Kuang 1,2, Jing Zeng 2,3, Lingling Tong1,2, Qianqi Liu 1,2, Huanxin Sun 1,2, Min Feng 1,2, Dongni Liang 1,2, Wei Wang 1,2 and Cheng Wang 1,2*  \n1 Department of Pathology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China, 2 Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, Sichuan, China, 3 Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China  \nObjective: This study evaluated the incidence of Microsatellite Instability-High (MSI-H) in patients with gynecologic cancers in a single gynecologic center and investigated the effect of immune checkpoint inhibitors (ICIs) in treating MSI-H in advanced or recurrent gynecologic cancers.  \nMethods: We conducted a retrospective study of patients diagnosed with gynecological cancers between June 2021 and May 2024 . We investigated their clinicopathological information, the results of microsatellite instability (MSI), the immunohistochemistry staining PD-L1 analyses, the molecular classiﬁcation testing, and the tumor response to treatment with ICIs.  \nResults: Among 1333 patients included in the analysis, the frequency of MSI-H was 1.3%(3/223) in cervical cancer, 25.7%(280/1091) in endometrial cancer, and 10. 5%(2/19) in ovarian or tubal and peritoneal cancer. When the patients were evaluated by histologic type, the frequency of MSI-H was 26.1%(241/921) inendometrioid adenocarcinoma and 35 . 1%(20/57) in mixed adenocarcinoma. Molecular classiﬁcation results for the 1020 cases that successfully underwent the tests were 71 for the POLE mutation (POLEmut) subtype, 271 for MMRdeﬁciency (MMRd) subtype, 571 for the non-speciﬁc molecular proﬁle (NSMP) subtype, and 107 for the p53 abnormality (p53abn) subtype. Thirty-ﬁve patients were treated with ICIs for at least one cycle. The objective response rate (ORR) was 34 .3%(95% CI, 19 . 1% to 52 . 2%) . Among the patients who achieved an objective response, the median time to respond was 2.65 months, and the median duration of response had not been reached. The median progressionfree survival (PFS) was 9 months (95% CI, 4 to 10), and the median overall survival (OS) had not been reached. Additionally, in the patients with endometrial cancer, the median PFS in MSI-H patients was 5 months versus 3 months in microsatellite  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nstable (MSS) patients (D = ","cbCaij3RTd6Qt051","https://ap.wps.com/l/cbCaij3RTd6Qt051","pdf",1859214,11,"English","# Objective\n# Methods\n# Results\n## MSI-H frequency by cancer type and histology\n## Molecular classification\n## ICI treatment outcomes\n# Conclusion","[{\"question\":\"What was the main objective of this study?\",\"answer\":\"The study evaluated the incidence of MSI-H in patients with gynecologic cancers at a single center and investigated the effect of immune checkpoint inhibitors (ICIs) in treating MSI-H in advanced or recurrent disease.\"},{\"question\":\"How was MSI-H frequency distributed among the major gynecologic cancer types?\",\"answer\":\"Among 1333 analyzed patients, MSI-H frequency was reported for cervical cancer (1.3%), endometrial cancer (25.7%), and ovarian/tubal and peritoneal cancer (10.5%). It also varied by histologic type.\"},{\"question\":\"What clinical benefit did ICIs show for MSI-H patients?\",\"answer\":\"For patients treated with ICIs, the objective response rate (ORR) was reported along with time to response and survival outcomes including progression-free survival (PFS) and overall survival (OS). The study concluded that ICIs provided clinical benefit in advanced or recurrent gynecologic cancer patients.\"}]","Frequency of microsatellite instability in gynecologic cancers and the efficacy of immune checkpoint inhibitors treated - real-world data from a single gynecologic center | PDF",1790183105,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21f189610ee4e286976379b129b6eccd.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97ee702612925b2f74fda201fbbb9457.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c601f39f86013f333f9991c825cf0a1b.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70b40346a7a45c1762015cfac1783969.webp",980,1385]